AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
Completed · Not applicable
Conditions studied: Breast Cancer
In brief
RATIONALE: AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving AZD2171 together with combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed and may kill more tumor cells. PURPOSE: This randomized clinical trial is studying how well giving AZD2171 together with combination chemotherapy works in treating women with locally advanced breast cancer.
Key facts
- Study ID
- NCT00310089
- Run by
- National Cancer Institute (NCI)
- People needed
- 33
- Starts
- 2006-01-01
- Expected to finish
- 2007-07-01
- Last updated by the study team
- 2013-06-20
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States
- Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School — New Brunswick, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.